Presentations to highlight Company's novel treatments for kidney diseases
PR Newswire
LOS ALTOS, Calif. , March 3, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta , M.D., Chief Executive Officer of Unicycive, will participate at two upcoming investor conferences in March.
Unicycive management will present at the following investor conferences:
Date/Time: | March 13-15, 2022 (Virtually and In-Person) |
Format: | On demand on-line presentation (available now) and 1x1 meetings |
Presenter: | Dr. Shalabh Gupta |
Webcast: |
Dr. Gupta's presentation at the ROTH conference will be archived in the Investor Relations section of the Company's website here .
To schedule a one-on-one meeting with Unicycive, please contact your ROTH representative. For questions or further information about Unicycive, please contact Anne Marie Fields of Stern IR at 212-362-1200 or submit your request to ir@unicycive.com .
Maxim Group 2nd Annual Virtual Growth Conference
Date/Time: | March 28, 2022 at 1:00 pm Eastern time |
Format: | Fireside Chat |
Moderator: | Jason McCarthy, Ph.D., Senior Biotechnology Analyst at Maxim Group |
Presenter: | Dr. Shalabh Gupta |
Webcast: |
To schedule a one-on-one meeting with Unicycive management, visit Virtual Growth Conference | M-Vest , where you can submit a request for a virtual meeting and where you can view an On-demand on-line corporate presentation delivered by Dr. Gupta.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com .
SOURCE Unicycive Therapeutics Inc.